#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Identified mechanisms for target molecule elevation in CKD patients are either a decrease in renal excretion , an increase in endogenous production or both .
2-1	14-24	Identified	event[2]	new[2]	coref	2-11[7_2]
2-2	25-35	mechanisms	event[2]	new[2]	_	_
2-3	36-39	for	event[2]	new[2]	_	_
2-4	40-46	target	event[2]|substance[3]|abstract[4]	new[2]|new[3]|new[4]	_	_
2-5	47-55	molecule	event[2]|substance[3]|abstract[4]	new[2]|new[3]|new[4]	_	_
2-6	56-65	elevation	event[2]|abstract[4]	new[2]|new[4]	_	_
2-7	66-68	in	event[2]|abstract[4]	new[2]|new[4]	_	_
2-8	69-72	CKD	event[2]|abstract[4]|abstract|person[6]	new[2]|new[4]|new|new[6]	coref|coref	4-16|9-2[84_6]
2-9	73-81	patients	event[2]|abstract[4]|person[6]	new[2]|new[4]|new[6]	_	_
2-10	82-85	are	_	_	_	_
2-11	86-92	either	event[7]|event[8]	giv[7]|giv[8]	coref|coref	2-11[8_7]|29-11[241_8]
2-12	93-94	a	event[7]|event[8]	giv[7]|giv[8]	_	_
2-13	95-103	decrease	event[7]|event[8]	giv[7]|giv[8]	_	_
2-14	104-106	in	event[7]|event[8]	giv[7]|giv[8]	_	_
2-15	107-112	renal	event[7]|event[8]|abstract[9]	giv[7]|giv[8]|new[9]	coref	3-38[29_9]
2-16	113-122	excretion	event[7]|event[8]|abstract[9]	giv[7]|giv[8]|new[9]	_	_
2-17	123-124	,	event[7]|event[8]	giv[7]|giv[8]	_	_
2-18	125-127	an	event[7]|event[8]|event[10]	giv[7]|giv[8]|new[10]	coref	9-7[86_10]
2-19	128-136	increase	event[7]|event[8]|event[10]	giv[7]|giv[8]|new[10]	_	_
2-20	137-139	in	event[7]|event[8]|event[10]	giv[7]|giv[8]|new[10]	_	_
2-21	140-150	endogenous	event[7]|event[8]|event[10]|abstract[11]	giv[7]|giv[8]|new[10]|new[11]	coref	3-10[0_11]
2-22	151-161	production	event[7]|event[8]|event[10]|abstract[11]	giv[7]|giv[8]|new[10]|new[11]	_	_
2-23	162-164	or	event[7]|event[8]	giv[7]|giv[8]	_	_
2-24	165-169	both	event[7]|event[8]	giv[7]|giv[8]	_	_
2-25	170-171	.	_	_	_	_

#Text=Thus , TMAO levels could result from variations in production levels ( including dietary precursor intake , TMA endogenous production from gut microbiota , TMA and TMAO intestinal absorption , and FMO3 enzymatic activity ) or from its renal excretion .
3-1	172-176	Thus	_	_	_	_
3-2	177-178	,	_	_	_	_
3-3	179-183	TMAO	abstract|abstract[13]	new|new[13]	coref|coref	3-10[16_13]|3-27
3-4	184-190	levels	abstract[13]	new[13]	_	_
3-5	191-196	could	_	_	_	_
3-6	197-203	result	_	_	_	_
3-7	204-208	from	_	_	_	_
3-8	209-219	variations	abstract[14]	new[14]	_	_
3-9	220-222	in	abstract[14]	new[14]	_	_
3-10	223-233	production	abstract[14]|abstract|abstract[16]	new[14]|giv|giv[16]	coref|coref	3-18[20_0]|6-16[59_16]
3-11	234-240	levels	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-12	241-242	(	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-13	243-252	including	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-14	253-260	dietary	abstract[14]|abstract[16]|event[18]	new[14]|giv[16]|new[18]	_	_
3-15	261-270	precursor	abstract[14]|abstract[16]|substance|event[18]	new[14]|giv[16]|new|new[18]	ana	4-27
3-16	271-277	intake	abstract[14]|abstract[16]|event[18]	new[14]|giv[16]|new[18]	_	_
3-17	278-279	,	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-18	280-283	TMA	abstract[14]|abstract[16]|abstract|abstract[20]	new[14]|giv[16]|new|giv[20]	coref	3-25
3-19	284-294	endogenous	abstract[14]|abstract[16]|abstract[20]	new[14]|giv[16]|giv[20]	_	_
3-20	295-305	production	abstract[14]|abstract[16]|abstract[20]	new[14]|giv[16]|giv[20]	_	_
3-21	306-310	from	abstract[14]|abstract[16]|abstract[20]	new[14]|giv[16]|giv[20]	_	_
3-22	311-314	gut	abstract[14]|abstract[16]|abstract[20]|abstract|plant[22]	new[14]|giv[16]|giv[20]|new|new[22]	_	_
3-23	315-325	microbiota	abstract[14]|abstract[16]|abstract[20]|plant[22]	new[14]|giv[16]|giv[20]|new[22]	_	_
3-24	326-327	,	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-25	328-331	TMA	abstract[14]|abstract[16]|abstract|event[25]	new[14]|giv[16]|giv|new[25]	coref	24-17
3-26	332-335	and	abstract[14]|abstract[16]|event[25]	new[14]|giv[16]|new[25]	_	_
3-27	336-340	TMAO	abstract[14]|abstract[16]|abstract|event[25]	new[14]|giv[16]|giv|new[25]	coref	4-12
3-28	341-351	intestinal	abstract[14]|abstract[16]|event[25]	new[14]|giv[16]|new[25]	_	_
3-29	352-362	absorption	abstract[14]|abstract[16]|event[25]	new[14]|giv[16]|new[25]	_	_
3-30	363-364	,	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-31	365-368	and	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-32	369-373	FMO3	abstract[14]|abstract[16]|abstract|abstract[27]	new[14]|giv[16]|new|new[27]	ana	3-38[0_27]
3-33	374-383	enzymatic	abstract[14]|abstract[16]|abstract[27]	new[14]|giv[16]|new[27]	_	_
3-34	384-392	activity	abstract[14]|abstract[16]|abstract[27]	new[14]|giv[16]|new[27]	_	_
3-35	393-394	)	abstract[14]|abstract[16]	new[14]|giv[16]	_	_
3-36	395-397	or	_	_	_	_
3-37	398-402	from	_	_	_	_
3-38	403-406	its	abstract|abstract[29]	giv|giv[29]	coref	7-6[67_29]
3-39	407-412	renal	abstract[29]	giv[29]	_	_
3-40	413-422	excretion	abstract[29]	giv[29]	_	_
3-41	423-424	.	_	_	_	_

#Text=This study was therefore designed to assess the exact changes in TMAO values according to CKD stages as determined by gold standard measurements of GFR and its potential modifications during renal metabolism .
4-1	425-429	This	abstract[30]	new[30]	coref	5-2[43_30]
4-2	430-435	study	abstract[30]	new[30]	_	_
4-3	436-439	was	_	_	_	_
4-4	440-449	therefore	_	_	_	_
4-5	450-458	designed	_	_	_	_
4-6	459-461	to	_	_	_	_
4-7	462-468	assess	_	_	_	_
4-8	469-472	the	abstract[31]	new[31]	_	_
4-9	473-478	exact	abstract[31]	new[31]	_	_
4-10	479-486	changes	abstract[31]	new[31]	_	_
4-11	487-489	in	abstract[31]	new[31]	_	_
4-12	490-494	TMAO	abstract[31]|abstract|abstract[33]	new[31]|giv|new[33]	coref	5-9
4-13	495-501	values	abstract[31]|abstract[33]	new[31]|new[33]	_	_
4-14	502-511	according	abstract[31]	new[31]	_	_
4-15	512-514	to	abstract[31]	new[31]	_	_
4-16	515-518	CKD	abstract[31]|abstract|abstract[35]	new[31]|giv|new[35]	coref|coref	5-13|6-4[54_35]
4-17	519-525	stages	abstract[31]|abstract[35]	new[31]|new[35]	_	_
4-18	526-528	as	abstract[31]|abstract[35]	new[31]|new[35]	_	_
4-19	529-539	determined	abstract[31]|abstract[35]	new[31]|new[35]	_	_
4-20	540-542	by	abstract[31]|abstract[35]	new[31]|new[35]	_	_
4-21	543-547	gold	abstract[31]|abstract[35]|substance|abstract[37]|abstract[38]	new[31]|new[35]|new|new[37]|new[38]	_	_
4-22	548-556	standard	abstract[31]|abstract[35]|abstract[37]|abstract[38]	new[31]|new[35]|new[37]|new[38]	_	_
4-23	557-569	measurements	abstract[31]|abstract[35]|abstract[38]	new[31]|new[35]|new[38]	_	_
4-24	570-572	of	abstract[31]|abstract[35]|abstract[38]	new[31]|new[35]|new[38]	_	_
4-25	573-576	GFR	abstract[31]|abstract[35]|abstract[38]|abstract	new[31]|new[35]|new[38]|new	coref	10-20
4-26	577-580	and	abstract[31]|abstract[35]	new[31]|new[35]	_	_
4-27	581-584	its	abstract[31]|abstract[35]|substance|abstract[41]	new[31]|new[35]|giv|new[41]	_	_
4-28	585-594	potential	abstract[31]|abstract[35]|abstract[41]	new[31]|new[35]|new[41]	_	_
4-29	595-608	modifications	abstract[31]|abstract[35]|abstract[41]	new[31]|new[35]|new[41]	_	_
4-30	609-615	during	abstract[31]|abstract[35]|abstract[41]	new[31]|new[35]|new[41]	_	_
4-31	616-621	renal	abstract[31]|abstract[35]|abstract[41]|event[42]	new[31]|new[35]|new[41]|new[42]	_	_
4-32	622-632	metabolism	abstract[31]|abstract[35]|abstract[41]|event[42]	new[31]|new[35]|new[41]|new[42]	_	_
4-33	633-634	.	_	_	_	_

#Text=In the present study , we confirmed that TMAO is increased in CKD based on an inverse , although weak , correlation ( r2 = 0.388 ) between plasma TMAO and mGFR .
5-1	635-637	In	_	_	_	_
5-2	638-641	the	abstract[43]	giv[43]	coref	10-1[91_43]
5-3	642-649	present	abstract[43]	giv[43]	_	_
5-4	650-655	study	abstract[43]	giv[43]	_	_
5-5	656-657	,	_	_	_	_
5-6	658-660	we	person	acc	ana	6-9
5-7	661-670	confirmed	_	_	_	_
5-8	671-675	that	_	_	_	_
5-9	676-680	TMAO	abstract	giv	coref	5-29[51_0]
5-10	681-683	is	_	_	_	_
5-11	684-693	increased	_	_	_	_
5-12	694-696	in	_	_	_	_
5-13	697-700	CKD	abstract	giv	coref	6-7
5-14	701-706	based	_	_	_	_
5-15	707-709	on	_	_	_	_
5-16	710-712	an	abstract[47]	new[47]	coref	6-13[57_47]
5-17	713-720	inverse	abstract[47]	new[47]	_	_
5-18	721-722	,	abstract[47]	new[47]	_	_
5-19	723-731	although	abstract[47]	new[47]	_	_
5-20	732-736	weak	abstract[47]	new[47]	_	_
5-21	737-738	,	abstract[47]	new[47]	_	_
5-22	739-750	correlation	abstract[47]	new[47]	_	_
5-23	751-752	(	abstract[47]	new[47]	_	_
5-24	753-755	r2	abstract[47]|abstract	new[47]|new	_	_
5-25	756-757	=	abstract[47]	new[47]	_	_
5-26	758-763	0.388	abstract[47]|abstract	new[47]|new	_	_
5-27	764-765	)	abstract[47]	new[47]	_	_
5-28	766-773	between	abstract[47]	new[47]	_	_
5-29	774-780	plasma	abstract[47]|substance|abstract[51]|abstract[52]	new[47]|new|giv[51]|new[52]	coref|coref|coref	6-16[0_51]|11-4|13-8[118_52]
5-30	781-785	TMAO	abstract[47]|abstract[51]|abstract[52]	new[47]|giv[51]|new[52]	_	_
5-31	786-789	and	abstract[47]|abstract[52]	new[47]|new[52]	_	_
5-32	790-794	mGFR	abstract[47]|abstract[52]|abstract	new[47]|new[52]|new	coref	13-10
5-33	795-796	.	_	_	_	_

#Text=Surprisingly , in all stages of CKD , we did not find any correlation between TMAO levels and its precursors , except a weak correlation with carnitine .
6-1	797-809	Surprisingly	_	_	_	_
6-2	810-811	,	_	_	_	_
6-3	812-814	in	_	_	_	_
6-4	815-818	all	abstract[54]	giv[54]	coref	10-11[95_54]
6-5	819-825	stages	abstract[54]	giv[54]	_	_
6-6	826-828	of	abstract[54]	giv[54]	_	_
6-7	829-832	CKD	abstract[54]|abstract	giv[54]|giv	coref	7-23
6-8	833-834	,	_	_	_	_
6-9	835-837	we	person	giv	ana	8-5
6-10	838-841	did	_	_	_	_
6-11	842-845	not	_	_	_	_
6-12	846-850	find	_	_	_	_
6-13	851-854	any	abstract[57]	giv[57]	ana	6-19[0_57]
6-14	855-866	correlation	abstract[57]	giv[57]	_	_
6-15	867-874	between	abstract[57]	giv[57]	_	_
6-16	875-879	TMAO	abstract[57]|abstract|abstract[59]|abstract[60]	giv[57]|giv|giv[59]|giv[60]	coref|coref|coref	6-16[60_59]|7-4|10-8[94_60]
6-17	880-886	levels	abstract[57]|abstract[59]|abstract[60]	giv[57]|giv[59]|giv[60]	_	_
6-18	887-890	and	abstract[57]|abstract[60]	giv[57]|giv[60]	_	_
6-19	891-894	its	abstract[57]|abstract[60]|abstract|animal[62]	giv[57]|giv[60]|giv|new[62]	coref|coref	6-23[63_0]|24-16[211_62]
6-20	895-905	precursors	abstract[57]|abstract[60]|animal[62]	giv[57]|giv[60]|new[62]	_	_
6-21	906-907	,	_	_	_	_
6-22	908-914	except	_	_	_	_
6-23	915-916	a	abstract[63]	giv[63]	coref	13-4[116_63]
6-24	917-921	weak	abstract[63]	giv[63]	_	_
6-25	922-933	correlation	abstract[63]	giv[63]	_	_
6-26	934-938	with	abstract[63]	giv[63]	_	_
6-27	939-948	carnitine	abstract[63]|substance	giv[63]|new	_	_
6-28	949-950	.	_	_	_	_

#Text=Measured clearances of TMAO showed a complete renal excretion of TMAO by glomerular filtration with a steady FE of 105 % during CKD , regardless of the stage .
7-1	951-959	Measured	abstract[65]	new[65]	coref	15-7[134_65]
7-2	960-970	clearances	abstract[65]	new[65]	_	_
7-3	971-973	of	abstract[65]	new[65]	_	_
7-4	974-978	TMAO	abstract[65]|abstract	new[65]|giv	coref	7-11
7-5	979-985	showed	_	_	_	_
7-6	986-987	a	abstract[67]	giv[67]	_	_
7-7	988-996	complete	abstract[67]	giv[67]	_	_
7-8	997-1002	renal	abstract[67]	giv[67]	_	_
7-9	1003-1012	excretion	abstract[67]	giv[67]	_	_
7-10	1013-1015	of	abstract[67]	giv[67]	_	_
7-11	1016-1020	TMAO	abstract[67]|abstract	giv[67]|giv	coref	8-21
7-12	1021-1023	by	abstract[67]	giv[67]	_	_
7-13	1024-1034	glomerular	abstract[67]|abstract|object[70]	giv[67]|new|new[70]	coref|coref	17-8|17-4[157_70]
7-14	1035-1045	filtration	abstract[67]|object[70]	giv[67]|new[70]	_	_
7-15	1046-1050	with	abstract[67]	giv[67]	_	_
7-16	1051-1052	a	abstract[67]|abstract[71]	giv[67]|new[71]	_	_
7-17	1053-1059	steady	abstract[67]|abstract[71]	giv[67]|new[71]	_	_
7-18	1060-1062	FE	abstract[67]|abstract[71]	giv[67]|new[71]	_	_
7-19	1063-1065	of	abstract[67]|abstract[71]	giv[67]|new[71]	_	_
7-20	1066-1069	105	abstract[67]|abstract[71]|abstract[72]	giv[67]|new[71]|new[72]	_	_
7-21	1070-1071	%	abstract[67]|abstract[71]|abstract[72]	giv[67]|new[71]|new[72]	_	_
7-22	1072-1078	during	abstract[67]|abstract[71]	giv[67]|new[71]	_	_
7-23	1079-1082	CKD	abstract[67]|abstract[71]|abstract	giv[67]|new[71]|giv	coref	10-14
7-24	1083-1084	,	_	_	_	_
7-25	1085-1095	regardless	_	_	_	_
7-26	1096-1098	of	_	_	_	_
7-27	1099-1102	the	abstract[74]	new[74]	_	_
7-28	1103-1108	stage	abstract[74]	new[74]	_	_
7-29	1109-1110	.	_	_	_	_

#Text=Unlike previous studies , we reported no evidence for effective contribution of tubular excretion or reabsorption during renal clearance of TMAO .
8-1	1111-1117	Unlike	_	_	_	_
8-2	1118-1126	previous	abstract[75]	new[75]	coref	11-13[105_75]
8-3	1127-1134	studies	abstract[75]	new[75]	_	_
8-4	1135-1136	,	_	_	_	_
8-5	1137-1139	we	person	giv	ana	9-5
8-6	1140-1148	reported	_	_	_	_
8-7	1149-1151	no	abstract[77]	new[77]	_	_
8-8	1152-1160	evidence	abstract[77]	new[77]	_	_
8-9	1161-1164	for	abstract[77]	new[77]	_	_
8-10	1165-1174	effective	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-11	1175-1187	contribution	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-12	1188-1190	of	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-13	1191-1198	tubular	abstract[77]|abstract[78]|abstract[79]	new[77]|new[78]|new[79]	coref	24-6[208_79]
8-14	1199-1208	excretion	abstract[77]|abstract[78]|abstract[79]	new[77]|new[78]|new[79]	_	_
8-15	1209-1211	or	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-16	1212-1224	reabsorption	abstract[77]|abstract[78]|abstract	new[77]|new[78]|new	coref	19-11[175_0]
8-17	1225-1231	during	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-18	1232-1237	renal	abstract[77]|abstract[78]|event[81]	new[77]|new[78]|new[81]	coref	14-13[0_81]
8-19	1238-1247	clearance	abstract[77]|abstract[78]|event[81]	new[77]|new[78]|new[81]	_	_
8-20	1248-1250	of	abstract[77]|abstract[78]|event[81]	new[77]|new[78]|new[81]	_	_
8-21	1251-1255	TMAO	abstract[77]|abstract[78]|event[81]|abstract	new[77]|new[78]|new[81]|giv	coref	9-11
8-22	1256-1257	.	_	_	_	_

#Text=In hemodialysis patients , we confirmed a greater increase in TMAO even though FR was similar to that of urea .
9-1	1258-1260	In	_	_	_	_
9-2	1261-1273	hemodialysis	abstract|person[84]	new|giv[84]	ana	12-21[0_84]
9-3	1274-1282	patients	person[84]	giv[84]	_	_
9-4	1283-1284	,	_	_	_	_
9-5	1285-1287	we	person	giv	ana	14-5
9-6	1288-1297	confirmed	_	_	_	_
9-7	1298-1299	a	event[86]	giv[86]	_	_
9-8	1300-1307	greater	event[86]	giv[86]	_	_
9-9	1308-1316	increase	event[86]	giv[86]	_	_
9-10	1317-1319	in	event[86]	giv[86]	_	_
9-11	1320-1324	TMAO	event[86]|abstract	giv[86]|giv	ana	9-18[89_0]
9-12	1325-1329	even	_	_	_	_
9-13	1330-1336	though	_	_	_	_
9-14	1337-1339	FR	abstract	new	_	_
9-15	1340-1343	was	_	_	_	_
9-16	1344-1351	similar	_	_	_	_
9-17	1352-1354	to	_	_	_	_
9-18	1355-1359	that	abstract[89]	giv[89]	coref	10-8[0_89]
9-19	1360-1362	of	abstract[89]	giv[89]	_	_
9-20	1363-1367	urea	abstract[89]|substance	giv[89]|new	coref	18-14
9-21	1368-1369	.	_	_	_	_

#Text=This study investigated for the first time TMAO levels in all stages of CKD using gold standard measures of GFR .
10-1	1370-1374	This	abstract[91]	giv[91]	coref	13-1[115_91]
10-2	1375-1380	study	abstract[91]	giv[91]	_	_
10-3	1381-1393	investigated	_	_	_	_
10-4	1394-1397	for	_	_	_	_
10-5	1398-1401	the	time[92]	new[92]	coref	23-14[0_92]
10-6	1402-1407	first	time[92]	new[92]	_	_
10-7	1408-1412	time	time[92]	new[92]	_	_
10-8	1413-1417	TMAO	abstract|abstract[94]	giv|giv[94]	coref|coref	11-3|12-1[108_94]
10-9	1418-1424	levels	abstract[94]	giv[94]	_	_
10-10	1425-1427	in	abstract[94]	giv[94]	_	_
10-11	1428-1431	all	abstract[94]|abstract[95]	giv[94]|giv[95]	coref	13-18[123_95]
10-12	1432-1438	stages	abstract[94]|abstract[95]	giv[94]|giv[95]	_	_
10-13	1439-1441	of	abstract[94]|abstract[95]	giv[94]|giv[95]	_	_
10-14	1442-1445	CKD	abstract[94]|abstract[95]|abstract	giv[94]|giv[95]|giv	coref	11-7
10-15	1446-1451	using	_	_	_	_
10-16	1452-1456	gold	abstract[97]	new[97]	_	_
10-17	1457-1465	standard	abstract[97]	new[97]	_	_
10-18	1466-1474	measures	abstract[97]	new[97]	_	_
10-19	1475-1477	of	abstract[97]	new[97]	_	_
10-20	1478-1481	GFR	abstract[97]|abstract	new[97]|giv	coref	12-26[114_0]
10-21	1482-1483	.	_	_	_	_

#Text=Results of TMAO plasma concentrations in CKD were in good accordance with previous studies .
11-1	1484-1491	Results	abstract[99]	new[99]	coref	17-1[154_99]
11-2	1492-1494	of	abstract[99]	new[99]	_	_
11-3	1495-1499	TMAO	abstract[99]|abstract|abstract[102]	new[99]|giv|new[102]	coref	12-2
11-4	1500-1506	plasma	abstract[99]|substance|abstract[102]	new[99]|giv|new[102]	coref	12-3
11-5	1507-1521	concentrations	abstract[99]|abstract[102]	new[99]|new[102]	_	_
11-6	1522-1524	in	abstract[99]|abstract[102]	new[99]|new[102]	_	_
11-7	1525-1528	CKD	abstract[99]|abstract[102]|abstract	new[99]|new[102]|giv	coref	13-18
11-8	1529-1533	were	_	_	_	_
11-9	1534-1536	in	_	_	_	_
11-10	1537-1541	good	abstract[104]	new[104]	ana	12-10[109_104]
11-11	1542-1552	accordance	abstract[104]	new[104]	_	_
11-12	1553-1557	with	abstract[104]	new[104]	_	_
11-13	1558-1566	previous	abstract[104]|abstract[105]	new[104]|giv[105]	coref	27-3[223_105]
11-14	1567-1574	studies	abstract[104]|abstract[105]	new[104]|giv[105]	_	_
11-15	1575-1576	.	_	_	_	_

#Text=Median TMAO plasma levels found herein were similar to those published by Stubbs et al. in 2015 , even though their data was based on estimated GFR .
12-1	1577-1583	Median	abstract[108]	giv[108]	coref	26-11[218_108]
12-2	1584-1588	TMAO	abstract|abstract[108]	giv|giv[108]	coref	13-8
12-3	1589-1595	plasma	substance|abstract[108]	giv|giv[108]	coref	26-11
12-4	1596-1602	levels	abstract[108]	giv[108]	_	_
12-5	1603-1608	found	abstract[108]	giv[108]	_	_
12-6	1609-1615	herein	abstract[108]	giv[108]	_	_
12-7	1616-1620	were	_	_	_	_
12-8	1621-1628	similar	_	_	_	_
12-9	1629-1631	to	_	_	_	_
12-10	1632-1637	those	abstract[109]	giv[109]	_	_
12-11	1638-1647	published	abstract[109]	giv[109]	_	_
12-12	1648-1650	by	abstract[109]	giv[109]	_	_
12-13	1651-1657	Stubbs	abstract[109]|person	giv[109]|new	_	_
12-14	1658-1660	et	abstract[109]	giv[109]	_	_
12-15	1661-1664	al.	abstract[109]	giv[109]	_	_
12-16	1665-1667	in	abstract[109]	giv[109]	_	_
12-17	1668-1672	2015	abstract[109]|time	giv[109]|new	_	_
12-18	1673-1674	,	_	_	_	_
12-19	1675-1679	even	_	_	_	_
12-20	1680-1686	though	_	_	_	_
12-21	1687-1692	their	person|abstract[113]	giv|new[113]	coref|coref	13-13[0_113]|21-10[187_0]
12-22	1693-1697	data	abstract[113]	new[113]	_	_
12-23	1698-1701	was	_	_	_	_
12-24	1702-1707	based	_	_	_	_
12-25	1708-1710	on	_	_	_	_
12-26	1711-1720	estimated	abstract[114]	giv[114]	_	_
12-27	1721-1724	GFR	abstract[114]	giv[114]	_	_
12-28	1725-1726	.	_	_	_	_

#Text=Another study reported a negative correlation between TMAO and mGFR but both data sets were restricted to CKD stages 3 or more severe .
13-1	1727-1734	Another	abstract[115]	giv[115]	coref	14-8[127_115]
13-2	1735-1740	study	abstract[115]	giv[115]	_	_
13-3	1741-1749	reported	_	_	_	_
13-4	1750-1751	a	abstract[116]	giv[116]	coref	26-7[216_116]
13-5	1752-1760	negative	abstract[116]	giv[116]	_	_
13-6	1761-1772	correlation	abstract[116]	giv[116]	_	_
13-7	1773-1780	between	abstract[116]	giv[116]	_	_
13-8	1781-1785	TMAO	abstract[116]|abstract|abstract[118]	giv[116]|giv|giv[118]	coref	14-16
13-9	1786-1789	and	abstract[116]|abstract[118]	giv[116]|giv[118]	_	_
13-10	1790-1794	mGFR	abstract[116]|abstract[118]|abstract	giv[116]|giv[118]|giv	coref	18-8
13-11	1795-1798	but	_	_	_	_
13-12	1799-1803	both	abstract[121]	new[121]	_	_
13-13	1804-1808	data	abstract|abstract[121]	giv|new[121]	coref	20-22[183_0]
13-14	1809-1813	sets	abstract[121]	new[121]	_	_
13-15	1814-1818	were	_	_	_	_
13-16	1819-1829	restricted	_	_	_	_
13-17	1830-1832	to	_	_	_	_
13-18	1833-1836	CKD	abstract|abstract[123]	giv|giv[123]	coref|coref	14-18|17-19[161_123]
13-19	1837-1843	stages	abstract[123]	giv[123]	_	_
13-20	1844-1845	3	abstract[123]	giv[123]	_	_
13-21	1846-1848	or	abstract[123]	giv[123]	_	_
13-22	1849-1853	more	abstract[123]	giv[123]	_	_
13-23	1854-1860	severe	_	_	_	_
13-24	1861-1862	.	_	_	_	_

#Text=To the best of our knowledge , no study has performed urinary clearance measures of TMAO in CKD .
14-1	1863-1865	To	_	_	_	_
14-2	1866-1869	the	abstract[124]	new[124]	_	_
14-3	1870-1874	best	abstract[124]	new[124]	_	_
14-4	1875-1877	of	abstract[124]	new[124]	_	_
14-5	1878-1881	our	abstract[124]|person|abstract[126]	new[124]|giv|new[126]	ana	16-22
14-6	1882-1891	knowledge	abstract[124]|abstract[126]	new[124]|new[126]	_	_
14-7	1892-1893	,	_	_	_	_
14-8	1894-1896	no	abstract[127]	giv[127]	coref	20-10[0_127]
14-9	1897-1902	study	abstract[127]	giv[127]	_	_
14-10	1903-1906	has	_	_	_	_
14-11	1907-1916	performed	_	_	_	_
14-12	1917-1924	urinary	abstract[129]	new[129]	_	_
14-13	1925-1934	clearance	event|abstract[129]	giv|new[129]	_	_
14-14	1935-1943	measures	abstract[129]	new[129]	_	_
14-15	1944-1946	of	abstract[129]	new[129]	_	_
14-16	1947-1951	TMAO	abstract[129]|abstract	new[129]|giv	coref	15-7
14-17	1952-1954	in	_	_	_	_
14-18	1955-1958	CKD	abstract	giv	coref	17-19
14-19	1959-1960	.	_	_	_	_

#Text=Previously , Hai et al. published TMAO clearances in control subjects , reporting a higher clearance of TMAO compared to creatinine , suggesting an active secretion of TMAO .
15-1	1961-1971	Previously	_	_	_	_
15-2	1972-1973	,	_	_	_	_
15-3	1974-1977	Hai	person	new	_	_
15-4	1978-1980	et	_	_	_	_
15-5	1981-1984	al.	_	_	_	_
15-6	1985-1994	published	_	_	_	_
15-7	1995-1999	TMAO	abstract|abstract[134]	giv|giv[134]	coref	15-18
15-8	2000-2010	clearances	abstract[134]	giv[134]	_	_
15-9	2011-2013	in	_	_	_	_
15-10	2014-2021	control	animal[135]	new[135]	coref	30-30[254_135]
15-11	2022-2030	subjects	animal[135]	new[135]	_	_
15-12	2031-2032	,	_	_	_	_
15-13	2033-2042	reporting	_	_	_	_
15-14	2043-2044	a	abstract[136]	new[136]	coref	18-1[163_136]
15-15	2045-2051	higher	abstract[136]	new[136]	_	_
15-16	2052-2061	clearance	abstract[136]	new[136]	_	_
15-17	2062-2064	of	abstract[136]	new[136]	_	_
15-18	2065-2069	TMAO	abstract[136]|abstract	new[136]|giv	coref	15-28
15-19	2070-2078	compared	abstract[136]	new[136]	_	_
15-20	2079-2081	to	abstract[136]	new[136]	_	_
15-21	2082-2092	creatinine	abstract[136]|substance	new[136]|new	coref	18-21
15-22	2093-2094	,	_	_	_	_
15-23	2095-2105	suggesting	_	_	_	_
15-24	2106-2108	an	substance[139]	new[139]	ana	16-3[0_139]
15-25	2109-2115	active	substance[139]	new[139]	_	_
15-26	2116-2125	secretion	substance[139]	new[139]	_	_
15-27	2126-2128	of	substance[139]	new[139]	_	_
15-28	2129-2133	TMAO	substance[139]|abstract	new[139]|giv	coref	16-24
15-29	2134-2135	.	_	_	_	_

#Text=Due to its low molecular weight ( 75 Da ) and soluble non ionizable nature , with minimal protein-bound fraction , we consider TMAO to be entirely filtered through the glomerular basement membrane , which is the main known elimination route for TMAO .
16-1	2136-2139	Due	_	_	_	_
16-2	2140-2142	to	_	_	_	_
16-3	2143-2146	its	substance|abstract[142]	giv|new[142]	coref	19-7
16-4	2147-2150	low	abstract[142]	new[142]	_	_
16-5	2151-2160	molecular	abstract[142]	new[142]	_	_
16-6	2161-2167	weight	abstract[142]	new[142]	_	_
16-7	2168-2169	(	_	_	_	_
16-8	2170-2172	75	person[143]	new[143]	_	_
16-9	2173-2175	Da	person[143]	new[143]	_	_
16-10	2176-2177	)	_	_	_	_
16-11	2178-2181	and	_	_	_	_
16-12	2182-2189	soluble	abstract[144]	new[144]	_	_
16-13	2190-2193	non	abstract[144]	new[144]	_	_
16-14	2194-2203	ionizable	abstract[144]	new[144]	_	_
16-15	2204-2210	nature	abstract[144]	new[144]	_	_
16-16	2211-2212	,	abstract[144]	new[144]	_	_
16-17	2213-2217	with	abstract[144]	new[144]	_	_
16-18	2218-2225	minimal	abstract[144]|abstract[145]	new[144]|new[145]	_	_
16-19	2226-2239	protein-bound	abstract[144]|abstract[145]	new[144]|new[145]	_	_
16-20	2240-2248	fraction	abstract[144]|abstract[145]	new[144]|new[145]	_	_
16-21	2249-2250	,	_	_	_	_
16-22	2251-2253	we	person	giv	ana	17-1
16-23	2254-2262	consider	_	_	_	_
16-24	2263-2267	TMAO	abstract	giv	coref	16-43
16-25	2268-2270	to	_	_	_	_
16-26	2271-2273	be	_	_	_	_
16-27	2274-2282	entirely	_	_	_	_
16-28	2283-2291	filtered	_	_	_	_
16-29	2292-2299	through	_	_	_	_
16-30	2300-2303	the	place[149]	new[149]	_	_
16-31	2304-2314	glomerular	place[149]	new[149]	_	_
16-32	2315-2323	basement	place|place[149]	new|new[149]	_	_
16-33	2324-2332	membrane	place[149]	new[149]	_	_
16-34	2333-2334	,	place[149]	new[149]	_	_
16-35	2335-2340	which	place[149]|abstract[151]	new[149]|new[151]	_	_
16-36	2341-2343	is	place[149]|abstract[151]	new[149]|new[151]	_	_
16-37	2344-2347	the	place[149]|abstract[151]	new[149]|new[151]	_	_
16-38	2348-2352	main	place[149]|abstract[151]	new[149]|new[151]	_	_
16-39	2353-2358	known	place[149]|abstract[151]	new[149]|new[151]	_	_
16-40	2359-2370	elimination	place[149]|abstract|abstract[151]	new[149]|new|new[151]	_	_
16-41	2371-2376	route	place[149]|abstract[151]	new[149]|new[151]	_	_
16-42	2377-2380	for	place[149]|abstract[151]	new[149]|new[151]	_	_
16-43	2381-2385	TMAO	place[149]|abstract[151]|abstract	new[149]|new[151]|giv	coref	17-7
16-44	2386-2387	.	_	_	_	_

#Text=Our results showed a likely complete TMAO glomerular filtration with a steady FE of TMAO , regardless of CKD stages .
17-1	2388-2391	Our	person|abstract[154]	giv|giv[154]	ana|coref	19-1|30-1[244_154]
17-2	2392-2399	results	abstract[154]	giv[154]	_	_
17-3	2400-2406	showed	_	_	_	_
17-4	2407-2408	a	object[157]	giv[157]	_	_
17-5	2409-2415	likely	object[157]	giv[157]	_	_
17-6	2416-2424	complete	object[157]	giv[157]	_	_
17-7	2425-2429	TMAO	abstract|object[157]	giv|giv[157]	coref	17-15
17-8	2430-2440	glomerular	abstract|object[157]	giv|giv[157]	_	_
17-9	2441-2451	filtration	object[157]	giv[157]	_	_
17-10	2452-2456	with	object[157]	giv[157]	_	_
17-11	2457-2458	a	object[157]|abstract[158]	giv[157]|new[158]	coref	21-6[186_158]
17-12	2459-2465	steady	object[157]|abstract[158]	giv[157]|new[158]	_	_
17-13	2466-2468	FE	object[157]|abstract[158]	giv[157]|new[158]	_	_
17-14	2469-2471	of	object[157]|abstract[158]	giv[157]|new[158]	_	_
17-15	2472-2476	TMAO	object[157]|abstract[158]|abstract	giv[157]|new[158]|giv	coref	18-1
17-16	2477-2478	,	_	_	_	_
17-17	2479-2489	regardless	_	_	_	_
17-18	2490-2492	of	_	_	_	_
17-19	2493-2496	CKD	abstract|abstract[161]	giv|giv[161]	coref	30-32
17-20	2497-2503	stages	abstract[161]	giv[161]	_	_
17-21	2504-2505	.	_	_	_	_

#Text=TMAO clearance was similar to that of mGFR , higher than that of urea , and lower than that of creatinine , suggesting that TMAO is neither secreted as creatinine nor reabsorbed as urea by renal tubules .
18-1	2506-2510	TMAO	abstract|abstract[163]	giv|giv[163]	ana	18-6[164_0]
18-2	2511-2520	clearance	abstract[163]	giv[163]	_	_
18-3	2521-2524	was	_	_	_	_
18-4	2525-2532	similar	_	_	_	_
18-5	2533-2535	to	_	_	_	_
18-6	2536-2540	that	abstract[164]	giv[164]	coref	18-25[0_164]
18-7	2541-2543	of	abstract[164]	giv[164]	_	_
18-8	2544-2548	mGFR	abstract[164]|abstract	giv[164]|giv	coref	21-21
18-9	2549-2550	,	_	_	_	_
18-10	2551-2557	higher	_	_	_	_
18-11	2558-2562	than	_	_	_	_
18-12	2563-2567	that	_	_	_	_
18-13	2568-2570	of	_	_	_	_
18-14	2571-2575	urea	substance	giv	coref	18-34
18-15	2576-2577	,	_	_	_	_
18-16	2578-2581	and	_	_	_	_
18-17	2582-2587	lower	_	_	_	_
18-18	2588-2592	than	_	_	_	_
18-19	2593-2597	that	_	_	_	_
18-20	2598-2600	of	_	_	_	_
18-21	2601-2611	creatinine	substance	giv	coref	18-30
18-22	2612-2613	,	_	_	_	_
18-23	2614-2624	suggesting	_	_	_	_
18-24	2625-2629	that	_	_	_	_
18-25	2630-2634	TMAO	abstract	giv	coref	19-14
18-26	2635-2637	is	_	_	_	_
18-27	2638-2645	neither	_	_	_	_
18-28	2646-2654	secreted	_	_	_	_
18-29	2655-2657	as	_	_	_	_
18-30	2658-2668	creatinine	substance	giv	coref	28-18
18-31	2669-2672	nor	_	_	_	_
18-32	2673-2683	reabsorbed	_	_	_	_
18-33	2684-2686	as	_	_	_	_
18-34	2687-2691	urea	substance	giv	_	_
18-35	2692-2694	by	_	_	_	_
18-36	2695-2700	renal	substance[171]	new[171]	_	_
18-37	2701-2708	tubules	substance[171]	new[171]	_	_
18-38	2709-2710	.	_	_	_	_

#Text=We however cannot exclude that the secretion rate exactly matched the reabsorption of TMAO .
19-1	2711-2713	We	person	giv	ana	25-1
19-2	2714-2721	however	_	_	_	_
19-3	2722-2728	cannot	_	_	_	_
19-4	2729-2736	exclude	_	_	_	_
19-5	2737-2741	that	_	_	_	_
19-6	2742-2745	the	abstract[174]	new[174]	coref	30-21[251_174]
19-7	2746-2755	secretion	substance|abstract[174]	giv|new[174]	_	_
19-8	2756-2760	rate	abstract[174]	new[174]	_	_
19-9	2761-2768	exactly	_	_	_	_
19-10	2769-2776	matched	_	_	_	_
19-11	2777-2780	the	abstract[175]	giv[175]	_	_
19-12	2781-2793	reabsorption	abstract[175]	giv[175]	_	_
19-13	2794-2796	of	abstract[175]	giv[175]	_	_
19-14	2797-2801	TMAO	abstract[175]|abstract	giv[175]|giv	coref	21-6
19-15	2802-2803	.	_	_	_	_

#Text=Furthermore , high fractional reabsorption of sodium indicates that study participants had no tubular impairment , which reinforces the validity of these data .
20-1	2804-2815	Furthermore	_	_	_	_
20-2	2816-2817	,	_	_	_	_
20-3	2818-2822	high	abstract[177]	new[177]	_	_
20-4	2823-2833	fractional	abstract[177]	new[177]	_	_
20-5	2834-2846	reabsorption	abstract[177]	new[177]	_	_
20-6	2847-2849	of	abstract[177]	new[177]	_	_
20-7	2850-2856	sodium	abstract[177]|substance	new[177]|new	_	_
20-8	2857-2866	indicates	_	_	_	_
20-9	2867-2871	that	_	_	_	_
20-10	2872-2877	study	abstract|person[180]	giv|new[180]	coref	30-7[245_0]
20-11	2878-2890	participants	person[180]	new[180]	_	_
20-12	2891-2894	had	_	_	_	_
20-13	2895-2897	no	abstract[181]	new[181]	_	_
20-14	2898-2905	tubular	abstract[181]	new[181]	_	_
20-15	2906-2916	impairment	abstract[181]	new[181]	_	_
20-16	2917-2918	,	abstract[181]	new[181]	_	_
20-17	2919-2924	which	abstract[181]	new[181]	_	_
20-18	2925-2935	reinforces	abstract[181]	new[181]	_	_
20-19	2936-2939	the	abstract[181]|abstract[182]	new[181]|new[182]	_	_
20-20	2940-2948	validity	abstract[181]|abstract[182]	new[181]|new[182]	_	_
20-21	2949-2951	of	abstract[181]|abstract[182]	new[181]|new[182]	_	_
20-22	2952-2957	these	abstract[181]|abstract[182]|abstract[183]	new[181]|new[182]|giv[183]	_	_
20-23	2958-2962	data	abstract[181]|abstract[182]|abstract[183]	new[181]|new[182]|giv[183]	_	_
20-24	2963-2964	.	_	_	_	_

#Text=However , the IQR of TMAO FE showed that some patients exhibited higher or lower clearances of TMAO compared to mGFR ; especially in the control group where the median FE of TMAO was 103 % [ IQR 55 – 144 ] .
21-1	2965-2972	However	_	_	_	_
21-2	2973-2974	,	_	_	_	_
21-3	2975-2978	the	abstract[184]	new[184]	_	_
21-4	2979-2982	IQR	abstract[184]	new[184]	_	_
21-5	2983-2985	of	abstract[184]	new[184]	_	_
21-6	2986-2990	TMAO	abstract[184]|abstract|abstract[186]	new[184]|giv|giv[186]	coref	21-18
21-7	2991-2993	FE	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
21-8	2994-3000	showed	_	_	_	_
21-9	3001-3005	that	_	_	_	_
21-10	3006-3010	some	person[187]	giv[187]	_	_
21-11	3011-3019	patients	person[187]	giv[187]	_	_
21-12	3020-3029	exhibited	_	_	_	_
21-13	3030-3036	higher	abstract[188]	new[188]	_	_
21-14	3037-3039	or	abstract[188]	new[188]	_	_
21-15	3040-3045	lower	abstract[188]	new[188]	_	_
21-16	3046-3056	clearances	abstract[188]	new[188]	_	_
21-17	3057-3059	of	abstract[188]	new[188]	_	_
21-18	3060-3064	TMAO	abstract[188]|abstract	new[188]|giv	coref	21-33
21-19	3065-3073	compared	abstract[188]	new[188]	_	_
21-20	3074-3076	to	abstract[188]	new[188]	_	_
21-21	3077-3081	mGFR	abstract[188]|abstract	new[188]|giv	coref	23-17[202_0]
21-22	3082-3083	;	_	_	_	_
21-23	3084-3094	especially	place[192]	new[192]	_	_
21-24	3095-3097	in	place[192]	new[192]	_	_
21-25	3098-3101	the	place[192]	new[192]	_	_
21-26	3102-3109	control	abstract|place[192]	new|new[192]	coref	30-30
21-27	3110-3115	group	place[192]	new[192]	_	_
21-28	3116-3121	where	place[192]	new[192]	_	_
21-29	3122-3125	the	place[192]|abstract[193]|abstract[195]	new[192]|new[193]|new[195]	_	_
21-30	3126-3132	median	place[192]|abstract[193]|abstract[195]	new[192]|new[193]|new[195]	_	_
21-31	3133-3135	FE	place[192]|abstract[193]|abstract[195]	new[192]|new[193]|new[195]	_	_
21-32	3136-3138	of	place[192]|abstract[193]|abstract[195]	new[192]|new[193]|new[195]	_	_
21-33	3139-3143	TMAO	place[192]|abstract[193]|abstract|abstract[195]	new[192]|new[193]|giv|new[195]	coref	23-6
21-34	3144-3147	was	place[192]|abstract[195]	new[192]|new[195]	_	_
21-35	3148-3151	103	place[192]|abstract[195]	new[192]|new[195]	_	_
21-36	3152-3153	%	place[192]|abstract[195]	new[192]|new[195]	_	_
21-37	3154-3155	[	_	_	_	_
21-38	3156-3159	IQR	_	_	_	_
21-39	3160-3162	55	_	_	_	_
21-40	3163-3164	–	_	_	_	_
21-41	3165-3168	144	_	_	_	_
21-42	3169-3170	]	_	_	_	_
21-43	3171-3172	.	_	_	_	_

#Text=This dispersion could be explained by several factors .
22-1	3173-3177	This	abstract[196]	new[196]	_	_
22-2	3178-3188	dispersion	abstract[196]	new[196]	_	_
22-3	3189-3194	could	_	_	_	_
22-4	3195-3197	be	_	_	_	_
22-5	3198-3207	explained	_	_	_	_
22-6	3208-3210	by	_	_	_	_
22-7	3211-3218	several	abstract[197]	new[197]	_	_
22-8	3219-3226	factors	abstract[197]	new[197]	_	_
22-9	3227-3228	.	_	_	_	_

#Text=First , urinary clearance of TMAO was not assessed at the exact same time points than mGFR , measured by inulin or iohexol clearance .
23-1	3229-3234	First	_	_	_	_
23-2	3235-3236	,	_	_	_	_
23-3	3237-3244	urinary	abstract[198]	new[198]	coref	23-23[205_198]
23-4	3245-3254	clearance	abstract[198]	new[198]	_	_
23-5	3255-3257	of	abstract[198]	new[198]	_	_
23-6	3258-3262	TMAO	abstract[198]|abstract	new[198]|giv	coref	24-6
23-7	3263-3266	was	_	_	_	_
23-8	3267-3270	not	_	_	_	_
23-9	3271-3279	assessed	_	_	_	_
23-10	3280-3282	at	_	_	_	_
23-11	3283-3286	the	abstract[201]	new[201]	_	_
23-12	3287-3292	exact	abstract[201]	new[201]	_	_
23-13	3293-3297	same	abstract[201]	new[201]	_	_
23-14	3298-3302	time	time|abstract[201]	giv|new[201]	_	_
23-15	3303-3309	points	abstract[201]	new[201]	_	_
23-16	3310-3314	than	_	_	_	_
23-17	3315-3319	mGFR	abstract[202]	giv[202]	coref	29-14[0_202]
23-18	3320-3321	,	abstract[202]	giv[202]	_	_
23-19	3322-3330	measured	abstract[202]	giv[202]	_	_
23-20	3331-3333	by	abstract[202]	giv[202]	_	_
23-21	3334-3340	inulin	abstract[202]|substance	giv[202]|new	_	_
23-22	3341-3343	or	abstract[202]	giv[202]	_	_
23-23	3344-3351	iohexol	abstract[202]|substance|abstract[205]	giv[202]|new|giv[205]	_	_
23-24	3352-3361	clearance	abstract[202]|abstract[205]	giv[202]|giv[205]	_	_
23-25	3362-3363	.	_	_	_	_

#Text=Second , the variability of TMAO excretion could also be related to the amount of ingested TMA precursors .
24-1	3364-3370	Second	_	_	_	_
24-2	3371-3372	,	_	_	_	_
24-3	3373-3376	the	abstract[206]	new[206]	_	_
24-4	3377-3388	variability	abstract[206]	new[206]	_	_
24-5	3389-3391	of	abstract[206]	new[206]	_	_
24-6	3392-3396	TMAO	abstract[206]|abstract|abstract[208]	new[206]|giv|giv[208]	coref|coref	26-14|30-22[0_208]
24-7	3397-3406	excretion	abstract[206]|abstract[208]	new[206]|giv[208]	_	_
24-8	3407-3412	could	_	_	_	_
24-9	3413-3417	also	_	_	_	_
24-10	3418-3420	be	_	_	_	_
24-11	3421-3428	related	_	_	_	_
24-12	3429-3431	to	_	_	_	_
24-13	3432-3435	the	abstract[209]	new[209]	_	_
24-14	3436-3442	amount	abstract[209]	new[209]	_	_
24-15	3443-3445	of	abstract[209]	new[209]	_	_
24-16	3446-3454	ingested	abstract[209]|animal[211]	new[209]|giv[211]	_	_
24-17	3455-3458	TMA	abstract[209]|abstract|animal[211]	new[209]|giv|giv[211]	_	_
24-18	3459-3469	precursors	abstract[209]|animal[211]	new[209]|giv[211]	_	_
24-19	3470-3471	.	_	_	_	_

#Text=We unfortunately did not administer standardized meals to avoid this bias .
25-1	3472-3474	We	person	giv	ana	26-3
25-2	3475-3488	unfortunately	_	_	_	_
25-3	3489-3492	did	_	_	_	_
25-4	3493-3496	not	_	_	_	_
25-5	3497-3507	administer	_	_	_	_
25-6	3508-3520	standardized	object[213]	new[213]	_	_
25-7	3521-3526	meals	object[213]	new[213]	_	_
25-8	3527-3529	to	_	_	_	_
25-9	3530-3535	avoid	_	_	_	_
25-10	3536-3540	this	abstract[214]	new[214]	_	_
25-11	3541-3545	bias	abstract[214]	new[214]	_	_
25-12	3546-3547	.	_	_	_	_

#Text=Yet , we did not find a significant correlation between plasma levels of TMAO and total protein intake .
26-1	3548-3551	Yet	_	_	_	_
26-2	3552-3553	,	_	_	_	_
26-3	3554-3556	we	person	giv	ana	29-1
26-4	3557-3560	did	_	_	_	_
26-5	3561-3564	not	_	_	_	_
26-6	3565-3569	find	_	_	_	_
26-7	3570-3571	a	abstract[216]	giv[216]	_	_
26-8	3572-3583	significant	abstract[216]	giv[216]	_	_
26-9	3584-3595	correlation	abstract[216]	giv[216]	_	_
26-10	3596-3603	between	abstract[216]	giv[216]	_	_
26-11	3604-3610	plasma	abstract[216]|substance|abstract[218]|abstract[219]	giv[216]|giv|giv[218]|giv[219]	coref	26-11[219_218]
26-12	3611-3617	levels	abstract[216]|abstract[218]|abstract[219]	giv[216]|giv[218]|giv[219]	_	_
26-13	3618-3620	of	abstract[216]|abstract[218]|abstract[219]	giv[216]|giv[218]|giv[219]	_	_
26-14	3621-3625	TMAO	abstract[216]|abstract[218]|abstract[219]|abstract	giv[216]|giv[218]|giv[219]|giv	coref	27-26
26-15	3626-3629	and	abstract[216]|abstract[219]	giv[216]|giv[219]	_	_
26-16	3630-3635	total	abstract[216]|abstract[219]|event[222]	giv[216]|giv[219]|new[222]	_	_
26-17	3636-3643	protein	abstract[216]|abstract[219]|substance|event[222]	giv[216]|giv[219]|new|new[222]	_	_
26-18	3644-3650	intake	abstract[216]|abstract[219]|event[222]	giv[216]|giv[219]|new[222]	_	_
26-19	3651-3652	.	_	_	_	_

#Text=Moreover , several studies in animal or cellular models have shown involvement of tubular transporters such as organic cation transporter 2 ( OCT2 ) in TMAO cellular uptake and efflux .
27-1	3653-3661	Moreover	_	_	_	_
27-2	3662-3663	,	_	_	_	_
27-3	3664-3671	several	abstract[223]	giv[223]	_	_
27-4	3672-3679	studies	abstract[223]	giv[223]	_	_
27-5	3680-3682	in	abstract[223]	giv[223]	_	_
27-6	3683-3689	animal	abstract[223]|person|abstract[225]	giv[223]|new|new[225]	_	_
27-7	3690-3692	or	abstract[223]|abstract[225]	giv[223]|new[225]	_	_
27-8	3693-3701	cellular	abstract[223]|abstract[225]	giv[223]|new[225]	_	_
27-9	3702-3708	models	abstract[223]|abstract[225]	giv[223]|new[225]	_	_
27-10	3709-3713	have	_	_	_	_
27-11	3714-3719	shown	_	_	_	_
27-12	3720-3731	involvement	abstract[226]	new[226]	_	_
27-13	3732-3734	of	abstract[226]	new[226]	_	_
27-14	3735-3742	tubular	abstract[226]|place[227]	new[226]|new[227]	_	_
27-15	3743-3755	transporters	abstract[226]|place[227]	new[226]|new[227]	_	_
27-16	3756-3760	such	abstract[226]|place[227]	new[226]|new[227]	_	_
27-17	3761-3763	as	abstract[226]|place[227]	new[226]|new[227]	_	_
27-18	3764-3771	organic	abstract[226]|place[227]|substance[228]|person[229]	new[226]|new[227]|new[228]|new[229]	_	_
27-19	3772-3778	cation	abstract[226]|place[227]|substance[228]|person[229]	new[226]|new[227]|new[228]|new[229]	_	_
27-20	3779-3790	transporter	abstract[226]|place[227]|person[229]	new[226]|new[227]|new[229]	_	_
27-21	3791-3792	2	abstract[226]|place[227]|person[229]	new[226]|new[227]|new[229]	_	_
27-22	3793-3794	(	abstract[226]|place[227]	new[226]|new[227]	_	_
27-23	3795-3799	OCT2	abstract[226]|place[227]|abstract	new[226]|new[227]|new	_	_
27-24	3800-3801	)	abstract[226]|place[227]	new[226]|new[227]	_	_
27-25	3802-3804	in	abstract[226]|place[227]	new[226]|new[227]	_	_
27-26	3805-3809	TMAO	abstract[226]|place[227]|abstract|abstract[232]	new[226]|new[227]|giv|new[232]	coref	29-6
27-27	3810-3818	cellular	abstract[226]|place[227]|abstract[232]	new[226]|new[227]|new[232]	_	_
27-28	3819-3825	uptake	abstract[226]|place[227]|abstract[232]	new[226]|new[227]|new[232]	_	_
27-29	3826-3829	and	abstract[226]|place[227]	new[226]|new[227]	_	_
27-30	3830-3836	efflux	abstract[226]|place[227]|abstract	new[226]|new[227]|new	ana	28-1
27-31	3837-3838	.	_	_	_	_

#Text=This , however , has not been confirmed in humans unlike what has been previously described for creatinine .
28-1	3839-3843	This	abstract	giv	_	_
28-2	3844-3845	,	_	_	_	_
28-3	3846-3853	however	_	_	_	_
28-4	3854-3855	,	_	_	_	_
28-5	3856-3859	has	_	_	_	_
28-6	3860-3863	not	_	_	_	_
28-7	3864-3868	been	_	_	_	_
28-8	3869-3878	confirmed	_	_	_	_
28-9	3879-3881	in	_	_	_	_
28-10	3882-3888	humans	animal	new	_	_
28-11	3889-3895	unlike	_	_	_	_
28-12	3896-3900	what	_	_	_	_
28-13	3901-3904	has	_	_	_	_
28-14	3905-3909	been	_	_	_	_
28-15	3910-3920	previously	_	_	_	_
28-16	3921-3930	described	_	_	_	_
28-17	3931-3934	for	_	_	_	_
28-18	3935-3945	creatinine	substance	giv	_	_
28-19	3946-3947	.	_	_	_	_

#Text=We observed that elevation of TMAO is mostly due to a decrease in mGFR rather than tubular dysfunction .
29-1	3948-3950	We	person	giv	_	_
29-2	3951-3959	observed	_	_	_	_
29-3	3960-3964	that	_	_	_	_
29-4	3965-3974	elevation	abstract[238]	new[238]	_	_
29-5	3975-3977	of	abstract[238]	new[238]	_	_
29-6	3978-3982	TMAO	abstract[238]|abstract	new[238]|giv	coref	30-21
29-7	3983-3985	is	_	_	_	_
29-8	3986-3992	mostly	_	_	_	_
29-9	3993-3996	due	_	_	_	_
29-10	3997-3999	to	_	_	_	_
29-11	4000-4001	a	event[240]|event[241]	new[240]|giv[241]	_	_
29-12	4002-4010	decrease	event[240]|event[241]	new[240]|giv[241]	_	_
29-13	4011-4013	in	event[240]|event[241]	new[240]|giv[241]	_	_
29-14	4014-4018	mGFR	event[240]|event[241]|abstract	new[240]|giv[241]|giv	_	_
29-15	4019-4025	rather	event[241]	giv[241]	_	_
29-16	4026-4030	than	event[241]	giv[241]	_	_
29-17	4031-4038	tubular	event[241]|abstract[243]	giv[241]|new[243]	_	_
29-18	4039-4050	dysfunction	event[241]|abstract[243]	giv[241]|new[243]	_	_
29-19	4051-4052	.	_	_	_	_

#Text=These results are in line with another recent study reporting that urinary TMAO/creatinine ratios ( used as a surrogate of TMAO excretion rate ) were not significantly different between control and CKD subjects .
30-1	4053-4058	These	abstract[244]	giv[244]	_	_
30-2	4059-4066	results	abstract[244]	giv[244]	_	_
30-3	4067-4070	are	_	_	_	_
30-4	4071-4073	in	_	_	_	_
30-5	4074-4078	line	_	_	_	_
30-6	4079-4083	with	_	_	_	_
30-7	4084-4091	another	abstract[245]	giv[245]	_	_
30-8	4092-4098	recent	abstract[245]	giv[245]	_	_
30-9	4099-4104	study	abstract[245]	giv[245]	_	_
30-10	4105-4114	reporting	abstract[245]	giv[245]	_	_
30-11	4115-4119	that	abstract[245]	giv[245]	_	_
30-12	4120-4127	urinary	abstract[245]|abstract[247]	giv[245]|new[247]	_	_
30-13	4128-4143	TMAO/creatinine	abstract[245]|abstract|abstract[247]	giv[245]|new|new[247]	_	_
30-14	4144-4150	ratios	abstract[245]|abstract[247]	giv[245]|new[247]	_	_
30-15	4151-4152	(	abstract[245]|abstract[247]	giv[245]|new[247]	_	_
30-16	4153-4157	used	abstract[245]|abstract[247]	giv[245]|new[247]	_	_
30-17	4158-4160	as	abstract[245]|abstract[247]	giv[245]|new[247]	_	_
30-18	4161-4162	a	abstract[245]|abstract[247]|abstract[248]	giv[245]|new[247]|new[248]	_	_
30-19	4163-4172	surrogate	abstract[245]|abstract[247]|abstract[248]	giv[245]|new[247]|new[248]	_	_
30-20	4173-4175	of	abstract[245]|abstract[247]|abstract[248]	giv[245]|new[247]|new[248]	_	_
30-21	4176-4180	TMAO	abstract[245]|abstract[247]|abstract[248]|abstract|abstract[251]	giv[245]|new[247]|new[248]|giv|giv[251]	_	_
30-22	4181-4190	excretion	abstract[245]|abstract[247]|abstract[248]|abstract|abstract[251]	giv[245]|new[247]|new[248]|giv|giv[251]	_	_
30-23	4191-4195	rate	abstract[245]|abstract[247]|abstract[248]|abstract[251]	giv[245]|new[247]|new[248]|giv[251]	_	_
30-24	4196-4197	)	abstract[245]|abstract[247]	giv[245]|new[247]	_	_
30-25	4198-4202	were	abstract[245]	giv[245]	_	_
30-26	4203-4206	not	abstract[245]	giv[245]	_	_
30-27	4207-4220	significantly	abstract[245]	giv[245]	_	_
30-28	4221-4230	different	abstract[245]	giv[245]	_	_
30-29	4231-4238	between	_	_	_	_
30-30	4239-4246	control	abstract|animal[254]	giv|giv[254]	_	_
30-31	4247-4250	and	animal[254]	giv[254]	_	_
30-32	4251-4254	CKD	abstract|animal[254]	giv|giv[254]	_	_
30-33	4255-4263	subjects	animal[254]	giv[254]	_	_
30-34	4264-4265	.	_	_	_	_
